Therapy against ischemic injury

Current Pharmaceutical Design

Volumn 19, Issue 25, 2013, Pages 4597-4621

  Guarini, Giacinta ^a   Huqi, Alda ^a   Capozza, Paola ^a   Morrone, Doralisa ^a   Donati, Francesca ^a   Marzilli, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adenosine; Ischemia reperfusion injury; Mitochondria; mPTP; No reflow; Postconditioning; Preconditioning; RISK and SAFE pathways; ROS

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; FONDAPARINUX; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PRASUGREL; TICAGRELOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; VERAPAMIL; VORAPAXAR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; ASPIRATION CATHETER; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONTINUOUS INFUSION; DRUG INDUCED DISEASE; EMBOLIC PROTECTION DEVICE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOLTER MONITORING; HUMAN; ISCHEMIC HEART DISEASE; ISCHEMIC POSTCONDITIONING; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; RHEOLYTIC THROMBECTOMY; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS ASPIRATION; TISSUE DOPPLER IMAGING; UNSTABLE ANGINA PECTORIS;

HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA; REPERFUSION INJURY;

EID: 84881333657     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319250008     Document Type: Article

References (299)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361(9351): 13-20.
2. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006; 3(9): 499-506.
3. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005; 26(6): 549-57.
4. Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960; 70: 68-78.
5. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74(5): 1124-36.
6. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357(11): 1121-35.
7. Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. Nov 1977; 56(5): 786-94.
8. Stone GW, Dixon SR, Grines CL, et al. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol 2007; 100(9): 1370-5.
9. Brodie BR, Webb J, Cox DA, et al. Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). Am J Cardiol 2007; 99(12): 1680-6.
10. Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol. 16 1993; 72(19): 13G-21G.
11. Jennings RB, Ganote CE. Structural changes in myocardium during acute ischemia. Circ Res. Sep 1974; 35 Suppl 3: 156-72.
12. Francone M, Bucciarelli-Ducci C, Carbone I, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54(23): 2145-53.
13. Kloner RA, Braunwald E. Observations on experimental myocardial ischaemia. Cardiovasc Res 1980; 14(7): 371-95.
14. Reffelmann T, Hale SL, Li G, et al. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2002; 282(2): H766-72.
15. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 2002; 87(2): 162-8.
16. Ambrosio G, Weisman HF, Mannisi JA, et al. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989; 80(6): 1846-61.
17. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993; 21(2): 537-45.
18. Kloner RA, Ganote CE, Whalen DA, Jr., et al. Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol 1974; 74(3): 399-422.
19. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54(6): 1496-508.
20. Manciet LH, Poole DC, McDonagh PF, et al. Microvascular compression during myocardial ischemia: mechanistic basis for noreflow phenomenon. Am J Physiol 1994; 266(4 Pt 2): H1541-50.
21. Carlson RE, Aisen AM, Buda AJ. Effect of reduction in myocardial edema on myocardial blood flow and ventricular function after coronary reperfusion. Am J Physiol 1992; 262(3 Pt 2): H641-8.
22. Tsao PS, Aoki N, Lefer DJ, et al. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990; 82(4): 1402-12.
23. Tsao PS, Lefer AM. Time course and mechanism of endothelial dysfunction in isolated ischemic-and hypoxic-perfused rat hearts. Am J Physiol 1990; 259(6 Pt 2): H1660-6.
24. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 1996; 32(4): 743-51.
25. Ma XL, Weyrich AS, Lefer DJ, et al. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993; 72(2): 403-12.
26. Meisel SR, Shapiro H, Radnay J, et al. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging. J Am Coll Cardiol 1998; 31(1): 120-5.
27. Scarabelli T, Stephanou A, Rayment N, et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation 2001; 104(3): 253-6.
28. Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94(4): 1621-8.
29. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79(5): 949-56.
30. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101(5): 570-80.
31. Heusch G, Schulz R, Haude M, et al. Coronary microembolization. J Mol Cell Cardiol 2004; 37(1): 23-31.
32. Taylor AJ, Bobik A, Berndt MC, et al. Experimental rupture of atherosclerotic lesions increases distal vascular resistance: a limiting factor to the success of infarct angioplasty. Arterioscler Thromb Vasc Biol 2002; 22(1): 153-60.
33. Jaffe MD, Quinn NK. Warm-up phenomenon in angina pectoris. Lancet 1980; 2(8201): 934-6.
34. Bankwala Z, Hale SL, Kloner RA. Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecho lamines mimics ischemic preconditioning. Circulation 1994; 90(2): 1023-8.
35. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59(4): 418-58.
36. Sadigh B, Quintana M, Sylven C, et al. The ischemic preconditioning effect of adenosine in patients with ischemic heart disease. Cardiovasc Ultrasound 2009; 7: 52.
37. Ovize M, Baxter GF, Di Lisa F, et al. POSTCONDITIONING AND PROTECTION FROM REPERFUSION INJURY: WHERE DO WE STAND? Cardiovascular Research 2010.
38. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: United at reperfusion. Pharmacology & Therapeutics 2007; 116(2): 173-91.
39. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285(2): H579-88.
40. Heusch G. Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur Heart J September 11, 2011.
41. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. Oct 4 2005; 112(14): 2143-8.
42. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv. Jul 2005; 65(3): 361-7.
43. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. Feb 26 2008; 117(8): 1037-44.
44. Iliodromitis EK, Georgiadis M, Cohen MV, et al. Protection from post-conditioning depends on the number of short ischemic insults in anesthetized pigs. Basic Res Cardiol. Nov 2006; 101(6): 502-7.
45. Yang XC, Liu Y, Wang LF, et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol. Oct 2007; 19(10): 424-30.
46. Lonborg J, Kelbaek H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv. Feb 1; 3(1): 34-41.
47. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. Jul 31 1993; 342(8866): 276-7.
48. Alkhulaifi AM, Yellon DM, Pugsley WB. Preconditioning the human heart during aorto-coronary bypass surgery. Eur J Cardiothorac Surg 1994; 8(5): 270-5; discussion 276.
49. Lu EX, Chen SX, Yuan MD, et al. Preconditioning improves myocardial preservation in patients undergoing open heart operations. Ann Thorac Surg 1997; 64(5): 1320-4.
50. Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87(3): 893-9.
51. Walsh SR, Tang T, Sadat U, et al. Cardioprotection by remote ischaemic preconditioning. Br J Anaesth 2007; 99(5): 611-6.
52. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007; 370(9587): 575-9.
53. Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 2009; 119(6): 820-7.
54. Rubio R, Berne RM. Regulation of coronary blood flow. Prog Cardiovasc Dis 1975; 18(2): 105-22.
55. Deussen A, Borst M, Kroll K, et al. Formation of Sadenosylhomocysteine in the heart. II: A sensitive index for regional myocardial underperfusion. Circ Res 1988; 63(1): 250-61.
56. Deussen A, Moser G, Schrader J. Contribution of coronary endothelial cells to cardiac adenosine production. Pflugers Arch 1986; 406(6): 608-14.
57. Hein TW, Kuo L. cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and K(ATP) channels. Circ Res 1999; 85(7): 634-42.
58. Erga KS, Seubert CN, Liang HX, et al. Role of A(2A)-adenosine receptor activation for ATP-mediated coronary vasodilation in guinea-pig isolated heart. Br J Pharmacol 2000; 130(5): 1065-75.
59. Schrader J, Bardenheuer H. Assessment of vasoactive metabolites released from the isolated guinea pig during heart hypoxia and beta-adrenergic stimulation. Basic Res Cardiol. Jul-Aug 1981; 76(4): 365-8.
60. Stowe DF. Heart bioassay of effluent of isolated, perfused guinea pig hearts to examine the role of metabolites regulating coronary flow during hypoxia. Basic Res Cardiol 1981; 76(4): 359-64.
61. Kalsner S. The effect of hypoxia on prostaglandin output and on tone in isolated coronary arteries. Can J Physiol Pharmacol 1977; 55(4): 882-7.
62. Michiels C, Arnould T, Knott I, et al. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am J Physiol. Apr 1993; 264(4 Pt 1): C866-74.
63. Dai XZ, Bache RJ. Effect of indomethacin on coronary blood flow during graded treadmill exercise in the dog. Am J Physiol 1984; 247(3 Pt 2): H452-8.
64. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84(1): 350-6.
65. Ganote CE, Armstrong S, Downey JM. Adenosine and A1 selective agonists offer minimal protection against ischaemic injury to isolated rat cardiomyocytes. Cardiovasc Res 1993; 27(9): 1670-6.
66. Miura T, Liu Y, Kita H, et al. Roles of mitochondrial ATPsensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol 2000; 35(1): 238-45.
67. Kitakaze M, Takashima S, Funaya H, et al. Temporary acidosis during reperfusion limits myocardial infarct size in dogs. Am J Physiol 1997; 272(5 Pt 2): H2071-8.
68. Auchampach JA, Gross GJ. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993; 264(5 Pt 2): H1327-36.
69. Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 2009; 53(8): 709-17.
70. Garlid KD, Paucek P, Yarov-Yarovoy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATPsensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 1997; 81(6): 1072-82.
71. Korge P, Honda HM, Weiss JN. Protection of cardiac mitochondria by diazoxide and protein kinase C: implications for ischemic preconditioning. Proc Natl Acad Sci U S A 2002; 99(5): 3312-7.
72. Stone GW. Angioplasty strategies in ST-segment-elevation myocardial infarction: part II: intervention after fibrinolytic therapy, integrated treatment recommendations, and future directions. Circulation 2008; 118(5): 552-66.
73. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101(18): 2154-9.
74. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34(6): 1711-20.
75. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 2003; 59(1): 1-9.
76. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, doubleblinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45(11): 1775-80.
77. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006; 27(20): 2400-5.
78. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute STsegment elevation myocardial infarction. Eur Heart J. 32(7): 867-77.
79. Werner GS, Lang K, Kuehnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57(4): 444-51.
80. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996; 39(2): 113-8.
81. Yui H, Imaizumi U, Beppu H, et al. Comparative effects of verapamil, nicardipine, and nitroglycerin on myocardial ischemia/reperfusion injury. Anesthesiol Res Pract 2011: 521084.
82. Nayler WG, Ferrari R, Williams A. Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 1980; 46(2): 242-8.
83. Boengler K, Buechert A, Heinen Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102(1): 131-5.
84. Nakano A, Liu GS, Heusch G, et al. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 2000; 32(7): 1159-67.
85. Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal 2009; 11(8): 1913-28.
86. Chai Y, Zhang DM, Lin YF. Activation of cGMP-Dependent Protein Kinase Stimulates Cardiac ATP-Sensitive Potassium Channels via a ROS/Calmodulin/CaMKII Signaling Cascade. PLoS ONE. 6(3): e18191.
87. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res.; 87(3): 406-23.
88. Ong SB, Subrayan S, Lim SY, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation.; 121(18): 2012-22.
89. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359(9314): 1269-75.
90. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112(9): 1284-8.
91. J E, Juneja MS, George T, et al. Prevention of no flow/slow reflow phenomenon in primary PCI by Nicorandil. Indian Heart J. May-Jun 2007; 59(3): 246-249.
92. Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels.; 26(4): 379-84.
93. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370(9597): 1483-93.
94. Matsuo H, Watanabe S, Watanabe T, et al. Prevention of noreflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. Am Heart J 2007; 154(5): 994 e991-6.
95. Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J 2008; 72(9): 1425-9.
96. Karmazyn M. The myocardial sodium-hydrogen exchanger (NHE) and its role in mediating ischemic and reperfusion injury. Keio J Med 1998; 47(2): 65-72.
97. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307 (Pt 1): 93-8.
98. Kim JS, Ohshima S, Pediaditakis P, et al. Nitric oxide: a signaling molecule against mitochondrial permeability transition-and pHdependent cell death after reperfusion. Free Radic Biol Med 2004; 37(12): 1943-50.
99. Armstrong JS. Mitochondrial membrane permeabilization: the sine qua non for cell death. Bioessays 2006; 28(3): 253-60.
100. Borutaite V, Mildaziene V, Brown GC, et al. Control and kinetic analysis of ischemia-damaged heart mitochondria: which parts of the oxidative phosphorylation system are affected by ischemia? Biochim Biophys Acta 1995; 1272(3): 154-8.
101. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Bmj 1997; 314(7093): 1512-5.
102. Yang YM, Zhu J, Tan HQ, et al. [Effect of high dose glucoseinsulin-potassium infusion in patients with acute ST-segment elevation myocardial infarction: analysis of 7510 patients in China as part of CREATE-ECLA study]. Zhonghua Yi Xue Za Zhi 2008; 88(26): 1806-10.
103. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulinpotassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Jama 2005; 293(4): 437-46.
104. Ceremuyaski L, Budaj A, Czepiel A, et al. Low-Dose Glucose-Insulin-Potassium Is Ineffective in Acute Myocardial Infarction: Results of a Randomized Multicenter Pol-GIK Trial. Cardiovascular Drugs and Therapy 1999; 13(3): 191-200.
105. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26(7): 650-61.
106. Mamas MA, Neyses L, Fath-Ordoubadi F. A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol. Summer; 15(2): e20-24.
107. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998; 41(4): 369-79.
108. Albacker T, Carvalho G, Schricker T, et al. High-dose insulin therapy attenuates systemic inflammatory response in coronary artery bypass grafting patients. Ann Thorac Surg 2008; 86(1): 20-7.
109. Dandona P, Chaudhuri A, Ghanim H, et al. Use of insulin to improve glycemic control in diabetes mellitus. Cardiovasc Drugs Ther 2008; 22(3): 241-51.
110. Cottin Y, Lhuillier I, Gilson L, et al. Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Fail 2002; 4(2): 181-4.
111. Matsui T, Tao J, del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104(3): 330-5.
112. Stegenga ME, van der Crabben SN, Levi M, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55(6): 1807-12.
113. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003; 41(8): 1404-7.
114. Carvalho G, Pelletier P, Albacker T, et al. Cardioprotective Effects of Glucose and Insulin Administration While Maintaining Normoglycemia (GIN Therapy) in Patients Undergoing Coronary Artery Bypass Grafting. J Clin Endocrinol Metab 2011; 96(5): 1469-77.
115. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 2000; 139(2 Pt 3): S115-9.
116. Di Lisa F, Canton M, Carpi A, et al. Mitochondrial injury and protection in ischemic pre-and postconditioning. Antioxid Redox Signal.; 14(5): 881-91.
117. Aldakkak M, Stowe DF, Heisner JS, et al. Enhanced Na+/H+ exchange during ischemia and reperfusion impairs mitochondrial bioenergetics and myocardial function. J Cardiovasc Pharmacol 2008; 52(3): 236-44.
118. Aldakkak M, Camara AK, Heisner JS, et al. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res.; 64(4): 381-92.
119. Chen Q, Hoppel CL, Lesnefsky EJ. Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria. J Pharmacol Exp Ther 2006; 316(1): 200-7.
120. Lesnefsky EJ, Chen Q, Moghaddas S, et al. Blockade of electron transport during ischemia protects cardiac mitochondria. J Biol Chem 2004; 279(46): 47961-7.
121. Nadtochiy SM, Burwell LS, Brookes PS. Cardioprotection and mitochondrial S-nitrosation: effects of S-nitroso-2-mercaptopropionyl glycine (SNO-MPG) in cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 2007; 42(4): 812-25.
122. D'Alonzo AJ, Grover GJ, Darbenzio RB, et al. In vitro effects of capsaicin: antiarrhythmic and antiischemic activity. Eur J Pharmacol 1995; 272(2-3): 269-78.
123. Hanley PJ, Ray J, Brandt U, et al. Halothane, isoflurane and sevoflurane inhibit NADH: ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol 2002; 544(Pt 3): 687-93.
124. Kawabata H, Ishikawa K. Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts. Hypertens Res 2003; 26(1): 107-10.
125. McClellan KJ, Plosker GL. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999; 58(1): 143-57.
126. Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26(8): 949-58.
127. Gambert S, Vergely C, Filomenko R, et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem. Feb 2006; 283(1-2): 147-152.
128. Monteiro P, Duarte AI, Goncalves LM, et al. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia. Eur J Pharmacol 2004; 503(1-3): 123-8.
129. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86(5): 580-8.
130. Khan M, Meduru S, Mostafa M, et al. Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling. J Pharmacol Exp Ther.; 333(2): 421-9.
131. Peng JJ, Ma ZM, Ren WL, et al. [Clinical outcomes of trimetazidine in patients with acute ST segment elevation myocardial infarction without ST segment resolution after primary percutaneous coronary intervention]. Zhonghua Yi Xue Za Zhi 2009; 89(20): 1399-401.
132. Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007; 7(2): 143-50.
133. Marzilli M. Does trimetazidine prevent myocardial injury after percutaneous coronary intervention? Nat Clin Pract Cardiovasc Med 2008; 5(1): 16-7.
134. Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992; 33(4): 486-91.
135. Tunerir B, Colak O, Alatas O, et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68(6): 2173-6.
136. Martins GF, Siqueira Filho AG, Santos JB, et al. Trimetazidine on ischemic injury and reperfusion in coronary artery bypass grafting. Arq Bras Cardiol.; 97(3): 209-16.
137. Nikolsky E, Grines CL, Cox DA, et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol 2007; 99(8): 1055-61.
138. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost.; 9 Suppl 1: 76-91.
139. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357(24): 2482-94.
140. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349-0.
141. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. Jan 12 2002; 324(7329): 71-86.
142. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
143. Figueredo VM, Diamond I, Zhou HZ, et al. Chronic dipyridamole therapy produces sustained protection against cardiac ischemiareperfusion injury. Am J Physiol 1999; 277(5 Pt 2): H2091-7.
144. Taniguchi M, Magata S, Suzuki T, et al. Dipyridamole protects the liver against warm ischemia and reperfusion injury. J Am Coll Surg 2004; 198(5): 758-69.
145. Riksen NP, Oyen WJG, Ramakers BP, et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 2005; 78(1): 52-9.
146. Tanzilli G, Greco C, Pasceri V, et al. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. Catheter Cardiovasc Interv.; 76(6): 787-93.
147. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-39.
148. Lewis BS MS, Fox KA, Halon DA, et al. CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am heart journal 2005; 150(6): 1177-84.
149. Mehta SR YS, Peters RJ, Bertrand ME, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
150. Aronow HD SS, Brennan DM, Berger PB, Topol EJ. CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am heart Journal 2009; 157(2): 369-74.
151. Mehta SR TJ, Eikelboom JW, Jolly SS, et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376(9748): 1233-43.
152. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J.; 32(23): 2999-3054.
153. Van de Werf F, Bax J, Betriu A, et al. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Rev Esp Cardiol 2009; 62(3): 293, e291-47.
154. Kanko M, Maral H, Akbas MH, et al. Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. Tohoku J Exp Med 2005; 205(2): 133-9.
155. Kanko M, Ozden M, Maral H, et al. Effect of clopidogrel on nitric oxide levels in an ischemia reperfusion model. J Cardiovasc Pharmacol 2006; 48(1): 797-801.
156. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706-17.
157. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med 2001; 345(7): 494-502.
158. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92(2): 311-6.
159. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109(25): 3171-5.
160. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88(3): 230-5.
161. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374(9694): 989-97.
162. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25): 1809-17.
163. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008; 5(12): 766-80.
164. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118(16): 1626-36.
165. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371(9621): 1353-63.
166. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27(9): 1038-47.
167. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045-57.
168. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation.; 122(11): 1056-67.
169. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for noninvasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ.342: d3527.
170. Wang K, Zhou X, Huang Y, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost.; 104(3): 609-17.
171. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3(8): 1800-14.
172. Vandendries ER, Hamilton JR, Coughlin SR, et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA 2007; 104(1): 288-92.
173. Strande J, Hsu A, Su J, et al. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Research in Cardiology 2007; 102(4): 350-8.
174. O'Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation.; 123(17): 1843-53.
175. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebocontrolled phase II study. Lancet 2009; 373(9667): 919-28.
176. Phillips DR, Conley PB, Sinha U, et al. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005; 3(8): 1577-89.
177. Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004; 43(2): 276-83.
178. Yang YJ, Zhao JL, You SJ, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 2006; 92(8): 1131-7.
179. Picchi A, Zaca V, Focardi M, et al. Beneficial effect of postprocedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon. Acute Card Care 2008; 10(2): 100-3.
180. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005; 150(5): 1015.
181. Kaul U, Sapra R, Singh B, et al. Abciximab During Rescue Angioplasty After Failed Thrombolysis. Asian Cardiovasc Thorac Ann 2001 2001; 9(1): 31-5.
182. Kong DF, Hasselblad V, Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. Sep 15 2003; 92(6): 651-5.
183. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. Aug 14 1997; 337(7): 447-52.
184. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Qwave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100(15): 1593-601.
185. Libersan D, Khalil A, Dagenais P, et al. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc Res 1998; 37(3): 656-66.
186. Mehta SR BW, Eikelboom JW, Flather M, et al. OASIS 5 and 6 Investigators. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST-and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008; 118(20): 2038-2046.
187. van Rees Vellinga TE PR, Yusuf S, Afzal R, Chrolavicius S, O'Donnell M, Mehta SR, Pluta W, Sacha J, Eikelboom JW. Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. Am heart J 2010; 160(6): 1049-55.
188. Montaigne D, Marechal X, Lancel S, et al. The synthetic pentasaccharide fondaparinux prevents coronary microvascular injury and myocardial dysfunction in the ischemic heart. Thromb Haemost 2008; 100(5): 912-9.
189. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for Patients with Acute Coronary Syndromes. New England Journal of Medicine 2006; 355(21): 2203-16.
190. Oldgren J BA, Granger CB, Khder Y, et al. for the RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, doubleblind, phase II trial. Eur Heart J 2011; 32(22): 2781-9.
191. Endo M, Hibi K, Shimizu T, et al. Impact of ultrasound attenuation and plaque rupture as detected by intravascular ultrasound on the incidence of no-reflow phenomenon after percutaneous coronary intervention in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv.; 3(5): 540-9.
192. Alfayoumi F, Srinivasan V, Geller M, et al. The no-reflow phenomenon: epidemiology, pathophysiology, and therapeutic approach. Rev Cardiovasc Med 2005; 6(2): 72-83.
193. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol 2009; 53(4): 309-15.
194. O'Regan DP, Ariff B, Neuwirth C, et al. Assessment of severe reperfusion injury with T2* cardiac MRI in patients with acute myocardial infarction. Heart.; 96(23): 1885-91.
195. Srinivasan M, Rihal C, Holmes DR, et al. Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes. Circulation 2009; 119(9): 1311-9.
196. Burzotta F, Trani C, Romagnoli E, et al. Manual thrombusaspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol 2005; 46(2): 371-6.
197. Silva-Orrego P, Colombo P, Bigi R, et al. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol 2006; 48(8): 1552-9.
198. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus Aspiration during Primary Percutaneous Coronary Intervention. New England Journal of Medicine 2008; 358(6): 557-67.
199. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008; 371(9628): 1915-20.
200. Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 2006; 48(2): 244-52.
201. Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol.; 56(16): 1298-306.
202. Liistro F, Grotti S, Angioli P, et al. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Interv 2009; 2(5): 376-83.
203. Lipiecki J, Monzy S, Durel N, et al. Effect of thrombus aspiration on infarct size and left ventricular function in high-risk patients with acute myocardial infarction treated by percutaneous coronary intervention. Results of a prospective controlled pilot study. Am Heart J 2009; 157(3): 583 e581-7.
204. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105(11): 1285-90.
205. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute STsegment elevation myocardial infarction: a randomized controlled trial. JAMA 2005; 293(9): 1063-72.
206. Muramatsu T, Kozuma K, Tsukahara R, et al. Comparison of myocardial perfusion by distal protection before and after primary stenting for acute myocardial infarction: angiographic and clinical results of a randomized controlled trial. Catheter Cardiovasc Interv 2007; 70(5): 677-82.
207. Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005; 112(10): 1462-9.
208. Guetta V, Mosseri M, Shechter M, et al. Safety and efficacy of the FilterWire EZ in acute ST-segment elevation myocardial infarction. Am J Cardiol 2007; 99(7): 911-5.
209. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61(3): 448-60.
210. Zhao ZQ, Morris CD, Budde JM, et al. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res 2003; 59(1): 132-42.
211. Yellon DM, Baxter GF. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999; 9(8): 245-9.
212. Davidson SM, Hausenloy D, Duchen MR, et al. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006; 38(3): 414-9.
213. Abdallah Y, Gkatzoflia A, Gligorievski D, et al. Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res 2006; 70(2): 346-53.
214. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007; 12(3-4): 217-34.
215. Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004; 95(2): 125-34.
216. Dirksen MT, Laarman GJ, Simoons ML, et al. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007; 74(3): 343-55.
217. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41(3): 508-15.
218. Pelosi L, Giacinti C, Nardis C, et al. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J 2007; 21(7): 1393-402.
219. Yang XM, Philipp S, Downey JM, et al. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006; 101(4): 311-8.
220. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003; 100(8): 4802-6.
221. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004; 18(9): 1031-3.
222. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359(5): 473-81.
223. Okorie MI, Bhavsar DD, Ridout D, et al. Postconditioning protects against human endothelial ischaemia-reperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore. Eur Heart J.; 32(10): 1266-74.
224. Snyders DJ. Structure and function of cardiac potassium channels. Cardiovasc Res 1999; 42(2): 377-90.
225. Sanada S, Kitakaze M, Asanuma H, et al. Role of mitochondrial and sarcolemmal K(ATP) channels in ischemic preconditioning of the canine heart. Am J Physiol Heart Circ Physiol 2001; 280(1): H256-63.
226. Costa AD, Garlid KD. Intramitochondrial signaling: interactions among mitoKATP, PKCepsilon, ROS, and MPT. Am J Physiol Heart Circ Physiol 2008; 295(2): H874-82.
227. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res 2004; 61(3): 372-85.
228. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94(7): 960-6.
229. Sanada S, Node K, Asanuma H, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J Am Coll Cardiol 2002; 40(5): 991-7.
230. Barandon L, Dufourcq P, Costet P, et al. Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ Res 2005; 96(12): 1299-306.
231. Vigneron F, Dos Santos P, Lemoine S, et al. GSK-3beta at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res.; 90(1): 49-56.
232. Bianchi P, Kunduzova O, Masini E, et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 2005; 112(21): 3297-305.
233. Morin D, Assaly R, Paradis S, et al. Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr Med Chem 2009; 16(33): 4382-98.
234. Camara AK, Lesnefsky EJ, Stowe DF. Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal.; 13(3): 279-347.
235. Zuurbier CJ, Eerbeek O, Meijer AJ. Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am J Physiol Heart Circ Physiol 2005; 289(1): H496-9.
236. Zuurbier CJ, Smeele KM, Eerbeek O. Mitochondrial hexokinase and cardioprotection of the intact heart. J Bioenerg Biomembr 2009; 41(2): 181-5.
237. Node K, Kitakaze M, Sato H, et al. Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning. Circulation 1997; 96(4): 1257-65.
238. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 2008; 103(5): 464-71.
239. Sato T, Saito T, Saegusa N, et al. Mitochondrial Ca2+-activated K+ channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 2005; 111(2): 198-203.
240. Feissner RF, Skalska J, Gaum WE, et al. Crosstalk signaling between mitochondrial Ca2+ and ROS. Front Biosci 2009; 14: 1197-218.
241. Sun JZ, Tang XL, Park SW, et al. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest 1996; 97(2): 562-76.
242. Kimura S, Zhang GX, Nishiyama A, et al. Role of NAD(P)H oxidase-and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005; 45(5): 860-6.
243. Chen L, Knowlton AA. Mitochondria and heart failure: new insights into an energetic problem. Minerva Cardioangiol.; 58(2): 213-29.
244. Kevin LG, Camara AK, Riess ML, et al. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003; 284(2): H566-74.
245. Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 2005; 70(2): 200-14.
246. Camara AK, Aldakkak M, Heisner JS, et al. ROS scavenging before 27 degrees C ischemia protects hearts and reduces mitochondrial ROS, Ca2+ overload, and changes in redox state. Am J Physiol Cell Physiol 2007; 292(6): C2021-31.
247. Kang SM, Lim S, Song H, et al. Allopurinol modulates reactive oxygen species generation and Ca2+ overload in ischemiareperfused heart and hypoxia-reoxygenated cardiomyocytes. Eur J Pharmacol 2006; 535(1-3): 212-9.
248. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97(22): 2259-67.
249. Hayward R, Campbell B, Shin YK, et al. Recombinant soluble Pselectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41(1): 65-76.
250. Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40(7): 1199-204.
251. Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297(1): 43-51.
252. Fu J, Lin G, Wu Z, et al. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochemical and Biophysical Research Communications 2006; 349(2): 504-12.
253. Fu J, Lin G, Wu Z, et al. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun 2006; 349(2): 504-512.
254. Yin M, van der Horst IC, van Melle JP, et al. Metformin improves cardiac function in a non-diabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. May 13.
255. Iwasa M, Yamada Y, Kobayashi H, et al. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol. Mar 22.
256. Goyal SN, Bharti S, Bhatia J, et al. Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes Metab.; 13(6): 533-41.
257. Li XY, Xu L, Lin GS, et al. Protective Effect of Caffeine Administration on Myocardial Ischemia/Reperfusion Injury in Rats. Shock. May 7.
258. Aleti S, Bansal D, Agrawal M, et al. Effect of chronic Angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions. J Invasive Cardiol.; 23(2): 72-75.
259. Lee EH, Lee HM, Chung CH, et al. Impact of intravenous lidocaine on myocardial injury after off-pump coronary artery surgery. Br J Anaesth.; 106(4): 487-93.
260. Hale SL, Kloner RA. Mild hypothermia as a cardioprotective approach for acute myocardial infarction: laboratory to clinical application. J Cardiovasc Pharmacol Ther.; 16(2): 131-9.
261. Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002; 40(11): 1928-34.
262. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45(9): 1406-12.
263. Niccoli G, Andreotti F, Marzo F, et al. Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest.; 41(11): 1210-9.
264. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA.; 305(18): 1863-72.
265. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart.; 97(19): 1560-5.
266. Iliodromitis EK, Andreadou I, Prokovas E, et al. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress attenuation. Basic Res Cardiol.; 105(2): 193-203.
267. Sanada S, Asanuma H, Minamino T, et al. Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 2004; 110(15): 2143-9.
268. Merla R, Daher IN, Ye Y, et al. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J 2007; 154(2): 391-402.
269. Shen Y, Wu H, Wang C, et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma. Eur J Pharmacol.; 649(1-3): 255-62.
270. Meijer P, Oyen WJ, Dekker D, et al. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol 2009; 29(6): 963-8.
271. Merla R, Ye Y, Lin Y, et al. The central role of adenosine in statininduced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol. Sep 2007; 293(3): H1918-28.
272. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004; 25(20): 1822-8.
273. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54(23): 2157-63.
274. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701-12.
275. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7): 605-13.
276. Booth EA, Marchesi M, Kilbourne EJ, et al. 17Beta-estradiol as a receptor-mediated cardioprotective agent. J Pharmacol Exp Ther 2003; 307(1): 395-401.
277. Babiker FA, Lips DJ, Delvaux E, et al. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol (Oxf) 2007; 189(1): 23-31.
278. Riess ML, Kevin LG, McCormick J, et al. Anesthetic preconditioning: the role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in Guinea pig isolated hearts. Anesth Analg 2005; 100(1): 46-53.
279. Riess ML, Stowe DF, Warltier DC. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol 2004; 286(5): H1603-1607.
280. Lucchinetti E, Ambrosio S, Aguirre J, et al. Sevoflurane inhalation at sedative concentrations provides endothelial protection against ischemia-reperfusion injury in humans. Anesthesiology 2007; 106(2): 262-268.
281. Landoni G, Fochi O, Tritapepe L, et al. Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol 2009; 75(5): 269-73.
282. Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a metaanalysis. Br J Anaesth 2006; 97(2): 127-36.
283. Jakobsen CJ, Berg H, Hindsholm KB, et al. The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007; 21(5): 664-71.
284. Landoni G, Zangrillo A, Fochi O, et al. Cardiac protection with volatile anesthetics in stenting procedures. J Cardiothorac Vasc Anesth 2008; 22(4): 543-7.
285. Borgers M, Thone F, Van Reempts J, et al. The role of calcium in cellular dysfunction. Am J Emerg Med 1983; 1(2): 154-61.
286. Reimer KA, Jennings RB. Verapamil in two reperfusion models of myocardial infarction. Temporary protection of severely ischemic myocardium without limitation of ultimate infarct size. Lab Invest 1984; 51(6): 655-66.
287. Yu W, Wang JJ, Gan WY, et al. [Effects of verapamil preconditioning on cardiac function in vitro and intracellular free Ca2+ and L-type calcium current in rat cardiomyocytes post ischemiareperfusion injury]. Zhonghua Xin Xue Guan Bing Za Zhi.; 38(3): 225-9.
288. Kitagawa Y, Bujo H, Takahashi K, et al. Impaired glucose tolerance is accompanied by decreased insulin sensitivity in tissues of mice implanted with cells that overexpress resistin. Diabetologia 2004; 47(10): 1847-53.
289. Sato N, Kobayashi K, Inoguchi T, et al. Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 2005; 146(1): 273-9.
290. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69(1): 76-85.
291. Rothwell SE, Richards AM, Pemberton CJ. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006; 349(1): 400-7.
292. Debinski M, Buszman PP, Milewski K, et al. Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. Int J Mol Med.; 27(6): 775-81.
293. Halestrap AP, Connern CP, Griffiths EJ, et al. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol Cell Biochem 1997; 174(1-2): 167-72.
294. Karlsson LO, Bergh N, Grip L. Cyclosporine A, 2.5 mg/kg, Does Not Reduce Myocardial Infarct Size in a Porcine Model of Ischemia and Reperfusion. J Cardiovasc Pharmacol Ther. May 13.
295. Jin Z, Duan W, Chen M, et al. The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial. Eur J Cardiothorac Surg.; 39(5): e90-96.
296. Gersh BJ, Antman EM. Selection of the optimal reperfusion strategy for STEMI: does time matter? Eur Heart J 2006; 27(7): 761-3.
297. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348(9030): 771-5.
298. Matsumura K, Jeremy RW, Schaper J, et al. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97(8): 795-804.
299. Scalia R, Pearlman S, Campbell B, et al. Time course of endothelial dysfunction and neutrophil adherence and infiltration during murine traumatic shock. Shock 1996; 6(3): 177-82.